Drug intelligence / Profile preview

SNA-XFSa

Development stage: Unknown
Lead developer: LABO'LIFE Belgium
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Sublingual

Overview

SNA-XFSa is a proprietary specific-nucleic-acid active ingredient used in Labo'Life's low-dose micro-immunotherapy product 2LXFS. It is supplied in homeopathic dilutions as one component of a multi-ingredient sublingual globule formulation that also includes cytokines, interferons, nucleic acids, and related SNA components. The product has been used and clinically studied in the context of fatigue associated with Epstein-Barr virus infection; no discrete molecular target or independently validated pharmacologic mechanism has been publicly established for SNA-XFSa itself. ([labolife.com](https://www.labolife.com/es/nuestros-tratamientos/medicamento-de-microinmunoterapia-2lxfs/))

Other names: Specific nucleic acid SNA-XFSa

Beyond the preview

Go deeper on SNA-XFSa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNA-XFSa.

Explore the full profile